DOCSLIB.ORG

Trends in Colorectal Cancer Mortality in Europe

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Trends in Colorectal Cancer Mortality in Europe BMJ Confidential: For Review Only Trends i n colorectal cancer mortality in Europe: an analysis of the WHO mortality database Journal: BMJ Manuscript ID: BMJ.2015.026370 Article Type: Research BMJ Journal: BMJ Date Submitted by the Author: 10-Apr-2015 Complete List of Authors: Ait Ouakrim, Driss; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Pizot, Cecile; International Prevention Research Institute (iPRI), Boniol, Magali; International Prevention Research Institute (iPRI), Malvezzi, Matteo; Universitá degli Studi di Milano, Department of Clinical Sciences and Community Health Boniol, Mathieu; International Prevention Research Institute (iPRI), ; University of Strathclyde Institute for Global Public Health at iPRI, Negri, Eva; IRCCS - Istituto di Ricerche Farmacologiche ‘Mario Negri’, Department of Epidemiology Bota, Maria; International Prevention Research Institute (iPRI), ; University of Strathclyde Institute for Global Public Health at iPRI, Jenkins, Mark; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Bleiberg, Harry; Jules Bordet Institute, Autier, Philippe; University of Strathclyde Institute of Global Public Health at iPRI, ; International Prevention Research Institute (iPRI), Keywords: colorectal cancer, mortality, screening, epidemiology https://mc.manuscriptcentral.com/bmj Page 1 of 33 BMJ 1 2 3 4 N = 3361 5 6 7 8 TrendsConfidential: in colorectal cancer mortality For in Review Europe: an analysis Only of the 9 10 WHO mortality database 11 12 13 14 1 2 15 Driss Ait Ouakrim Research Fellow , Cécile Pizot Research Officer , Magali Boniol Assistant 16 Statistician 2, Matteo Malvezzi Post Doctoral Fellow 3, Mathieu Boniol Vice-President 17 Biostatistics 2, 4, Eva Negri Head of laboratory 5, Maria Bota Research Officer 2, 4 , Mark A Jenkins 18 1 6 19 Professor and Director , Harry Bleiberg Professor Emeritus , Philippe Autier Vice-President 2, 4 20 Population Research . 21 22 23 1 Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, 24 25 University of Melbourne, 3010, Australia 26 2 International Prevention Research Institute (iPRI), 69006 Lyon, France 27 28 3 Department of Clinical Sciences and Community Health, Universitá degli Studi di Milano, 29 30 20156 Milan, Italy 31 4 University of Strathclyde Institute for Global Public Health at iPRI, 69006 Lyon, France 32 33 5 Department of Epidemiology, IRCCS - Istituto di Ricerche Farmacologiche ‘Mario Negri’, 20156 34 Milan, Italy. 35 36 6 Jules Bordet Institute, 1000 Brussels, Belgium 37 38 39 40 Correspondence: Dr Philippe Autier, International Prevention Research Institute (iPRI), Cours 41 Lafayette 95, 69006 Lyon Cedex 08, France; E-mail: [email protected]; website : www.i- 42 pri.org. 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 https://mc.manuscriptcentral.com/bmj BMJ Page 2 of 33 1 2 3 Abstract (n=297) 4 5 Objectives: To examine changes in colorectal cancer (CRC) mortality in 34 European countries 6 7 between 1989 and 2011 8 Confidential: For Review Only 9 Design: Retrospective trend analysis. 10 11 12 Data source: World Health Organisation mortality database. 13 14 Population: Female and male colorectal cancer deaths between 1989 and 2011. 15 16 17 Main outcomes measures: Time trends in colorectal cancer mortality rates using join point 18 19 regression analysis. Rates were age adjusted using the European Standard Population. 20 21 Results: From 1989 to 2011, declines in CRC mortality of more than 25% in men and 30% in 22 23 women occurred in Austria, Switzerland, Germany, the United Kingdom, Belgium, the Czech 24 25 Republic, Luxemburg and Ireland. In contrast, CRC mortality rates declined by less than 15% in 26 27 the Netherlands and Sweden for both sexes. Increases of 28 to 45% were observed in men in 28 Spain, Portugal and Greece that were not observed in women. Smaller or no declines occurred 29 30 in most Central European countries. Substantial mortality increases of 20 to 102% occurred in 31 32 Croatia, Macedonia, and Romania for both sexes and in most Eastern European countries for 33 34 men. In countries with declining CRC mortality, declines were generally more important for 35 36 women and people aged less than 65 years. Overall, from 1989 to 2011, CRC mortality in the 27 37 38 European member states has decreased by 13% for men and by 27% for women. As a 39 40 comparison, In the United States, CRC mortality declined by 40% for men and by 39% for 41 42 women. 43 44 Conclusions: There is considerable disparity in the level of CRC mortality between European 45 46 countries, as well as between men and women and between age categories. Countries with the 47 48 greatest declines in CRC mortality are characterised by greater accessibility to screening 49 50 services, especially endoscopic screening, and specialised care. In countries where rates are 51 52 sharply increasing, lifestyle factors such as poor diet and alcohol drinking also play a major role. 53 54 55 56 57 58 59 60 2 https://mc.manuscriptcentral.com/bmj Page 3 of 33 BMJ 1 2 3 Introduction 4 5 6 Colorectal cancer (CRC) is the second most commonly diagnosed cancer in the world and has 7 8 poorConfidential: prognosis when metastasised to lymph For nodes orReview distant organs. In 2012, Only it was estimated 9 1 10 that 241.6 thousand European men were diagnosed with CRC and 113.2 thousand died from it. 11 For European women, 205.2 thousand CRC cases and 101.5 thousand CRC deaths were 12 13 recorded that year.1 Estimations also indicated substantial differences in CRC mortality across 14 15 European countries.2 16 17 18 Over the last two decades in Europe, early detection of CRC has increased through screening 19 20 and easier access to endoscopic removal of adenomatous polyps (the commonest CRC 21 precursor lesion).3 At the same time, new CRC treatments have been developed and their 22 23 availability improved.4 Taken together, these factors would be expected to lead to a decrease in 24 25 CRC mortality over time; however, effectiveness and access to these mortality-reducing factors 26 27 may not be equal across age groups, sex, and nationality. Further, the prevalence of some of 28 29 the main risk factors for CRC has been increasing (e.g. adiposity and sedentary lifestyle) and is 30 5 31 unequally distributed between countries. 32 33 In order to better understand the possible reasons underlying the heterogeneity in CRC 34 35 mortality across European countries, we analysed age and sex-specific trends in CRC mortality 36 37 rates from 1970 to 2011 in 34 European countries. We were most interested in recent CRC 38 39 mortality trends (1989-2011) because the most profound changes in screening and treatment 40 41 efficiency took place after 1988. 42 43 Methods 44 45 46 Mortality data 47 48 Number of CRC deaths was obtained from the World Health Organisation (WHO) mortality 49 6 50 database for 34 European countries for the period 1970–2011. For the sake of comparison, we 51 52 also extracted data for the United States of America (USA). 53 54 Between 1970 and 2011, data on cause of death was classified using three versions of the 55 56 international Classification of Diseases (ICD). We defined CRC mortality as any death with an 57 58 ICD 8 code of A048-A049, an ICD 9 code of B093-B094, or an ICD 10 code of C18-C21. We also 59 60 3 https://mc.manuscriptcentral.com/bmj BMJ Page 4 of 33 1 2 3 included any death with an ICD code for cancers of the anus and/or anal canal because it was 4 5 unclear from the database how some countries used the different ICD coding schemes to 6 7 classify cancers into the various CRC sub-sites—“colon”, “recto-sigmoid junction”, “rectum”, 8 Confidential: For Review Only 9 “anus” and “anal canal”. 10 11 For a majority of Western European countries, data were available for most of or the period of 12 13 interest. Cyprus was not included because data were only available for four years (1999, 2000, 14 15 2004, 2006). For Switzerland, data were available until 2010. Furthermore, a change in coding 16 17 practice in 1994 resulted in an over-reporting of cancer mortality before 1994. We therefore 18 19 applied a correction factor of 0·94 to all mortality rates before 1995, as recommended by Lutz 20 7 21 et al. For most central and eastern European countries, data were available since the early-mid 22 23 1980s until 2009 – 10, with the exception of Bulgaria for which data were available for the 24 25 entire period. For Slovakia and the Republic of Macedonia data were available from 1991 and 26 27 1992 respectively, until 2010. Years for which data were missing are presented in 28 Supplementary Table 1. 29 30 31 Statistical analyses 32 33 We used the direct method and age-specific population estimates from the WHO mortality 34 35 database 6 to compute age-adjusted CRC mortality rates according to the age distribution of the 36 37 standard European population.8 Joinpoint regression analysis over the whole period was 38 39 performed to identify years where statistically significant changes in mortality trends occurred. 40 41 Annual percent changes (APCs) (relative change) were then computed for each country, by 42 43 fitting a regression line to the natural logarithm of the rates on the period 1989-2011 and over 44 45 the last five years of available data (2007-2011). Because of missing data, regression was fitted 46 over the period 1992 – 2010 for Slovakia and 1991 – 2010 for Macedonia.
Load more

Recommended publications
  • Current Awareness Service, February, 2011
    Current Awareness Services February 2011 American Journal of Epidemiology Volume 172, Issue 7 (1October 2010) How to Be a Department Chair of Epidemiology: A Survival Guide Roberta B. Ness and Jonathan M. Samet Pages: 747-751 A Pooled Analysis of Extremely Low-Frequency Magnetic Fields and Childhood Brain Tumors L. Kheifets, A. Ahlbom, C. M. Crespi, M. Feychting, C. Johansen, J. Monroe, M. F. G. Murphy, S. Oksuzyan, S. Preston-Martin, E. Roman, T. Saito, D. Savitz, J. Schüz, J. Simpson, J. Swanson, T. Tynes, P. Verkasalo, and G. Mezei Pages: 752-761 ORIGINAL CONTRIBUTION A Melanoma Epidemic in Iceland: Possible Influence of Sunbed Use Clarisse Héry, Laufey Tryggvadóttir, Thorgeir Sigurdsson, Elínborg Ólafsdóttir, Bardur Sigurgeirsson, Jon G. Jonasson, Jon H. Olafsson, Mathieu Boniol, Graham B. Byrnes, Jean-François Doré, and Philippe Autier Pages: 762-767 Invited Commentary: Invited Commentary: A Sunbed Epidemic? Marianne Berwick Pages: 768-770 Response to Invited Commentary: Autier et al. Respond to “A Sunbed Epidemic?” Philippe Autier, Laufey Tryggvadóttir, Thorgeir Sigurdsson, Elínborg Ólafsdóttir, Bardur Sigurgeirsson, Jon G. Jonasson, Jon H. Olafsson, Graham B. Byrnes, Clarisse Héry, Jean- François Doré, and Mathieu Boniol Pages: 771-772 Alcoholic Beverages and Prostate Cancer in a Prospective US Cohort Study Joanne L. Watters, Yikyung Park, Albert Hollenbeck, Arthur Schatzkin, and Demetrius Albanes Pages: 773-780 The Potentially Modifiable Burden of Incident Heart Failure Due to Obesity: The Atherosclerosis Risk in Communities Study Laura R. Loehr, Wayne D. Rosamond, Charles Poole, Ann Marie McNeill, Patricia P. Chang, Anita Deswal, Aaron R. Folsom, and Gerardo Heiss Pages: 781-789 Chronic and Acute Effects of Coal Tar Pitch Exposure and Cardiopulmonary Mortality Among Aluminum Smelter Workers Melissa C.
    [Show full text]
  • Operational Guidance Forvictim Assistance Responsive to Gender
    Victim assistance responsive to gender and other diversity aspects OPERATIONAL GUIDANCE The present publication was produced thanks to the financial support of the Italian Cooperation. Its content, however, is the sole responsibility of GMAP and does not reflect the views of the Italian Government. Table of contents List of abbreviations 5 Acknowledgments 6 Foreword 8 Introduction 11 Purpose of the operational guidance 14 Audience 15 Methodology 16 Limitations 17 Definitions 17 Structure 21 Services 23 Understanding the challenges (data collection) 23 Emergency and ongoing medical care 30 Rehabilitation 31 Psychological and psycho-social support 34 Socio-economic inclusion 37 Laws and policies 43 Affected States 45 Donors 49 Sources 51 Guidelines and Reports 51 Academic articles 55 Blogs, study cases and witnesses 57 © Jorge Henao, Colombia, 2010. GMAP - Guidances 2018 - Abbreviations & Preface Abbreviations ACAP III: Afghan Civilian Assistance Program ALSO: Afghanistan Landmine Survivor Organisation APMBC: Anti-Personnel Mine Ban Convention CCD: Community Center for the Disabled CCM: Convention on Cluster Munitions CCW: Convention on Certain Conventional Weapons CEDAW: Convention on the Elimination of all forms of Discrimination Against Women CRC: Convention on the Rights of the Child CRPD: Convention on the Rights of Persons with Disabilities DCP: Disability Creation Process ERW: Explosive Remnants of War GMAP: Gender and Mine Action Programme HI: Humanity & Inclusion (formerly known as Handicap International) HQ: Headquarters ICF:
    [Show full text]
  • Ipri Biennial Report 2015 - 2016
    12/2016 Creation iPRI Africa 07/2016 12th NCID 07/2015 11th NCID 06/2011 07/2011 7th NCID Epidemiology and Biostatistics 02/2012 World Published Breast Cancer Report Published 12/2009 MOU 07/2014 10th NCID U. Dundee 07/2010 First Summer School 10/2013 State of Oncology 2013 07/2010 6th NCID Published iPRI 04/2009 iPRI Founded 06/2012 Boyle 07/2013 9th NCID awarded LLD (honoris causa) 12/2010 Boyle Inducted Hungarian Science Academy 09/2012 Autier PhD Erasmus University 07/2010 06/2013 Creation of World Prevention Alliance Strathclyde Institute of 01/2013 Founded Global Public Health at iPRI Mullie professorship VUB 03/2013 Alcohol: Science, Policy and Public Health Published iPRI Biennial Per indicium ad excellentia R e port 2015 - 2016 © iPRI 2017 Biennial Report International Prevention Research Institute 95 Cours Lafayette 69006 Lyon, France +33472171199 | www.i-pri.org | [email protected] 2015 - 2016 Are we moving too fast? Perhaps we are - going too fast. Perhaps we are driving ahead, leaving too many people behind, quite literally in the dust. Perhaps we are not doing enough for the disen- franchised in low resource countries and for the poorest among us. iPRI believes in progress. We believe in providing the best possible evidence for better global health. But we are doubly committed to ensuring that our knowledge be a conduit for better health, not just in privileged quarters, but in the most destitute ones as well. All scientific and policy roads must lead to prevention and better health for all. iPRI Biennial Report 2015 - 2016 ©2017, International Prevention Research Institute, Lyon, France Contents cannot be copied or otherwise reproduced without express consent of iPRI.
    [Show full text]
  • The Journal of Disaster Studies and Management
    Volume 13 No. 1 1989 The Journal of Disaster Studies and Management Contents Agriculture and Food Security in Ethiopia NICHOLAS WINER The Food and Nutrition Surveillance Systems of Chad and Mali: the "SAP" after two years P. AUTIER et al. The Relief Operation in Puno District, Peru, after the 1986 Floods of Lake Titicaca L. SZTORCH, V. GICQUEL and J.C. DESENCLOS The Role of Socio-Economic Data in Food Needs Assessment and Monitoring J. SHOHAM and E. CLAY Diet and Nutrition during Drought: an Indian Experience N. PRALHAD RAO A case Study of Social Behaviour in a Natural Disaster: the Olivares landslide (Spain) J.L.G. GARCIA and M.V.S. PARRA Experiences of Non-Governmental Organisations in the Targeting of Emergency Food Aid J. BORTON and J. SHOHAM Seminar on Bangladesh Floods H. BRAMMER International Conference on the greenhouse effect and coastal areas of Bangladesh H. BRAMMER Forthcoming Events Book Reviews Basil Blackwell for the Relief and Development Institute DISASTERS The Journal of Disaster Studies and Management EDITOR Fred Cuny, Intertect, Derrick Jelliffe, School of Charles Melville, Faculty of Dallas, Texas Public Health, University of Oriental Studies, Bruce Currey Winrock California, Los Angeles University of Cambridge international Institute for ^ ^echat. Centre de ASSISTANT EDITOR Agricultural Development, Recherche sur Susan York, Relief and Bangladesh 1'Epidemiologie des Development Institute lan Davis, Disaster Desastres, 1'Ecole de Sante EDITORIAL BOARD ^"^ puu ue Universite oxford^TT ^ oxfordo , ^ ' Hugh Brammer, Relief P^Y ^^ ' ^ Catholique de Louvain, and Development Institute Frances D'Souza, Dept. of Brussels (Book Reviews Editor) Biological Anthropology, _, , , University of Oxford /-i.
    [Show full text]
  • Resource Mobilization: Methodological Guidelines
    Resource Mobilization: Methodological Guidelines Mukesh Chawla Research Associate Data for Decision Making Project Department of Population and International Health Harvard School of Public Health Peter Berman Associate Professor of International Health Economics Department of Population and International Health Harvard School of Public Health August 1996 Data for Decision Making Project Table of Contents Acknowledgements ....................................................................................... 1 1. Introduction ........................................................................................... 2 2. Strategies for Resource Mobilization ........................................................ 5 3. Tax Revenues ......................................................................................... 8 4. User Charges ........................................................................................ 11 Design and Implementation of User Fees ....................................................... 12 Impact of User Fees on the Health System .................................................... 16 5. Health Insurance .................................................................................. 24 Design and Implementation of Insurance System ............................................ 27 Impact of Insurance on the Health System .................................................... 32 6. Guidelines for the DDM/HHRAA Field Case Studies ................................. 37 Objectives ...............................................................................................
    [Show full text]
  • Section of Early Detection & Prevention (Edp)
    SECTION OF EARLY DETECTION & PREVENTION (EDP) THE SECTION OF EARLY DETECTION AND PREVENTION COMPRISES THREE GROUPS: Section Head THE PREVENTION GROUP (PRE), THE QUALITY ASSURANCE GROUP (QAS) AND THE Dr Rengaswamy Sankaranarayanan SCREENING GROUP (SCR). The Section seeks to provide evidence as to which primary and secondary prevention interventions are appropriate, effective and cost-effective in lowering the global burden of breast, cervical, oral, colorectal, skin and prostate cancers. This approach includes studying the means to implement integrated and quality-assured interventions in routine settings in different parts of the world. These research topics are in tune with the overall mission of the Agency in that they aim to reduce cancer burden by prevention. SECTION OF EARLY DETECTION & PREVENTION 105 106 biENNIAL REPORT 2008/2009 PREVENTION GROUP (PRE) Group Head Dr Philippe Autier Scientists Dr Mathieu Boniol Dr Graham Byrnes (until April 2009-moved to CIN/BST) Secretariat Ms Asiedua Asante Ms Anne Sophie Hameau (until March 2008) Ms Laurence Marnat (February 2008-May 2008) Visiting scientists Prof Brian Cox (from June 2008 to December 2008) Dr Jean-Francois Dore Dr Jan Alvar Lindencrona (until March 2008) Ms Carolyn Nickson (March 2009-May 2009) Prof Peter Selby (July 2009-December 2009) Ms Mary Jane Sneyd (June 2009-December 2009) Clerks Ms Murielle Colombet (until December 2008) Myriam Adjal (until February 2009) Students Lorraine Bernard (February 2008-August 2008) Maria Bota (July 2008-August 2008) Anne Elie Carsin (January 2008-April 2008) Gwendoline Chaize (May 2008-August 2008) Clementine Joubert (March 2008-August 2008) Alice Koechlin (May 2009-August 2009) Anthony Montella (June 2008-August2008) PhD students: Clarisse Hery (from June 2008) Isabelle Chaillol (from October 2008) PREVENTION GROUP 107 THE OVERALL GOAL OF THE PREVENTION GROUP IS TO EVALUATE THE IMPACT OF PREVENTION ACTIVITIES.
    [Show full text]
  • Mammography Screening Shows Limited Effect on Breast Cancer Mortality in Sweden
    Journal of the National Cancer Institute Contact: Zachary Rathner [email protected] 301-841-1286 CI Mammography Screening Shows Limited Effect on Breast Cancer Downloaded from https://academic.oup.com/jnci/article/104/14/NP/2517022 by guest on 01 October 2021 Mortality in Sweden Breast cancer mortality statistics in Sweden are consistent with studies that have reported that screening has limited or no impact on breast cancer mortality among women aged 40-69, according to a study published July 17 in the Journal of the National Cancer Institute. Since 1974, Swedish women aged 40-69 have increasingly been offered mammography screening, with nationwide cover- age peaking in 1997. Researchers set out to determine if mortality trends would be reflected accordingly. In order to determine this, Philippe Autier, M.D., of the International Prevention Research Institute (iPRI) in France and colleagues, looked at data from the Swedish Board of Health and Welfare from 1960-2009 to analyze trends in breast cancer mortality in women aged age 40 and older by the county in which they lived. The researchers compared actual mortality trends with the theoretical outcomes using models in which screening would result in mortality reductions of 10%, 20%, and 30%. The researchers expected that screening would be associated with a gradual reduction in mortality, especially because Swedish mammography trials and observational studies have suggested that mammography leads to a reduction in breast cancer mortality. In this study, however, they found that breast cancer mortality rates in Swedish women started to decrease in 1972, before the introduction of mammography, and have continued to decline at a rate similar to that in the prescreening period.
    [Show full text]
  • Sunbed Use, Sunscreen Use, Childhood Sun Exposure, and Cutaneous Melanoma
    Sunbed use, sunscreen use, childhood sun exposure, and cutaneous melanoma Philippe Autier Sunbed use, sunscreen use, childhood sun exposure, and cutaneous melanoma Philippe Autier 1 2 Sunbed use, Sunscreen use, Childhood Sun Exposure, and Cutaneous Melanoma Gebruik zonnebank, gebruik zonnecrèmes, blootstelling van de zon bij kinderen en melanoma van de huid Thesis To obtain the degree of Doctor from the Erasmus University Rotterdam by command of the rector magnificus Prof. dr. H.G. Schmidt, and in accordance with the decision of the Doctorate Board The public defence shall be held on Wednesday 12th of October 2011 at 11: 30 am by Philippe Autier Born in Naast (Belgium) 3 Doctoral Committee Promotors: Prof.dr. J.W.W. Coebergh Prof.dr. A.M.M. Eggermont Inner Committee: Prof.dr. A. Burdorf Prof. F. De Gruijl Prof.dr. H.A.M. Neumann Other members: Prof.dr. W. Bergman Prof.dr. R. Kanaar Prof.dr. R. MacKie Prof.dr. W.J. Mooi 4 For Anne, Anton and Gilles 5 Table of content Section 1: Preface Section 2: Artificial UV tanning Background as of 1992 Overview of ecological and observational studies Reviews and meta‐analyses Further data from descriptive studies Epidemiological or human experiments data supporting out findings Epidemiological or human experiments data challenging out findings Articles displayed as part of this section Section 3: Sunscreens and wearing of clothes Background as of 1992 Overview of observational studies on 5‐MOP sunscreens Overview of observational studies on sunscreens Randomised controlled trials Reviews Epidemiological
    [Show full text]
  • The Forthcoming Inexorable Decline of Cutaneous Melanoma Mortality in Light-Skinned Populations
    *Manuscript with amendments highlighted The forthcoming inexorable decline of cutaneous melanoma mortality in light-skinned populations Philippe Autier, MD 1,2 ; Alice Koechlin, MSc 1,2; Mathieu Boniol, PhD 1,2 1 University of Strathclyde Institute of Global Public Health at iPRI, International Prevention Research Institute , 95 Cours Lafayette, 69006 Lyon, France 2 International Prevention Research Institute (iPRI), 95 Cours Lafayette, 69006 Lyon, France Corresponding author: Dr Philippe Autier, International Prevention Research Institute (iPRI), 95 Cours Lafayette, 69006 Lyon, France E-mail: [email protected]; website: www.i-pri.org 1 Abstract Background: Reasons underlying time changes in cutaneous melanoma mortality in light- skinned populations are not well understood. An analysis of long-term time trends in melanoma mortality was carried out after regrouping countries in homogeneous regions. Methods: Using the WHO mortality database, age-period-cohort models were fitted for seven regions where the majority of population is light-skinned. Cohort effects are denoted as changes in rates occurring at different time in steadily older age groups. Period effects are denoted as changes in rates occurring simultaneously in several age groups. Findings: Cohort effects better explained changes in melanoma mortality over time than period effects. Lifetime risk to die from melanoma increased in successive generations from 1875 until a peak year. Peak years were for subjects born in 1936-40 in Oceania, 1937-43 in North America, 1941-42 in Northern Europe, 1945-53 in UK and Ireland, 1948 in Western Europe, and 1957 in Central Europe. After peak years, lifetime risk of melanoma death gradually decreased in successive generations and risks of subjects born in 1990-95 were back to risk levels observed for subjects born before 1900-05.
    [Show full text]
  • Drug Donation Practices in Bosnia I Herzegovina
    ug o at o act ces os a e zegov a 1 DRUG DONATION PRACTICES IN BOSNIA I HERZEGOVINA Patrick BERCKMANS (MD) Véronique DAWANS (Economist) & Gérard Schmets (MAE) Daniel Vandenbergh (Ph) Philippe Autier (MD) Francine Matthys (MD) 1996-1997 Study supported by a grant from Médecins Sans Frontières - Belgium 996 997 AEDES 2 Drug Donation Practices in Bosnia i Herzegovina ACKNOWLEDGEMENT Thanks are due to Médecins Sans Frontières-Belgium for funding this study and to its field staff in Sarajevo, Mostar and Tuzla for providing logistical support in Bosnia I Herzegovina. Valuable input and assistance were provided by a number of people and organisations in Bosnia I Herzegovina, Europe and North America, particularly contributions from Bradley Brigham, Pharmaciens Sans Frontières in Mostar, Mark Raijmakers, WEMOS, Bas van der Heide, Health Action International, and Dr. Stephen L. Willets, Chartered Environmental Manager. AEDES 1996-1997 ug o at o act ces os a e zegov a 3 EXECUTIVE SUMMARY Background: War in Bosnia and Herzegovina disorganized the health system. Many areas became totally dependent on foreign humanitarian assistance for the provision of medical supplies. In that context, large quantities of drugs and medical material were donated. Methods: An investigation was carried out at the end of 1996 to evaluate the donation practices of drugs and disposable medical materials during the war in Bosnia and Herzegovina. In the course of a survey in Central Bosnia (August 1996), interviews were conducted in Sarajevo, Mostar and Tuzla with representatives of the national and cantonal health authorities, international agencies, including the World Health Organization, the Office of the United Nations High Commissioner for Refugees and the European Commission Humanitarian Office, and the major non governmental organizations implementing drug supply and distribution programs in Bosnia and Herzegovina.
    [Show full text]
  • Drug Donations in Post-Emergency Situations
    Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized DRUG DONATIONS IN POST-EMERGENCY SITUATIONS Philippe Autier, Ramesh Govindaraj, Robin Gray, Rama Lakshminarayanan, Homira G. Nassery, and Gerard Schmets June 2002 Health, Nutrition and Population (HNP) Discussion Paper This series is produced by the Health, Nutrition, and Population Family (HNP) of the World Bank's Human Development Network (HNP Discussion Paper). The papers in this series aim to provide a vehicle for publishing preliminary and unpolished results on HNP topics to encourage discussion and debate. The findings, interpretations, and conclusions expressed in this paper are entirely those of the author(s) and should not be attributed in any manner to the World Bank, the World Health Organization (WHO), L’Agence Européenne pour le Développement et la Santé (AEDES), or to their affiliated organizations or to members of their Board of Executive Directors or the countries they represent. Citation and the use of material presented in this series should take into account this provisional character. For free copies of papers in this series please contact the individual authors whose name appears on the paper. Enquiries about the series and submissions should be made directly to the Editor in Chief. Submissions should have been previously reviewed and cleared by the sponsoring department which will bear the cost of publication. No additional reviews will be undertaken after submission. The sponsoring department and authors bear full responsibility for the quality of the technical contents and presentation of material in the series. Since the material will be published as presented, authors should submit an electronic copy in a predefined format as well as three camera-ready hard copies (copied front to back exactly as the author would like the final publication to appear).
    [Show full text]
  • STATE of HAWAII Testimony COMMENTING on HB0102-HD1
    DAVID Y. IGE ELIZABETH A. CHAR, M.D. GOVERNOR OF HAWAII DIRECTOR OF HEALTH STATE OF HAWAII DEPARTMENT OF HEALTH P. O. Box 3378 Honolulu, HI 96801-3378 [email protected] Testimony COMMENTING on HB0102-HD1 RELATING TO SUNSCREENS REPRESENTATIVE AARON LING JOHANSON, CHAIR REPRESENTATIVE LISA KITAGAWA, VICE CHAIR HOUSE COMMITTEE ON CONSUMER PROTECTION AND COMMERCE Hearing Date: 2/17/2021 Room Number: VideoConference 1 Fiscal Implications: This measure may impact the priorities identified in the Governor’s 2 Executive Budget Request for the Department of Health’s (Department) appropriations and 3 personnel priorities. 4 Department Testimony: HB0102 seeks to add avobenzone and octocrylene to the list of active 5 ingredients restricted from sale or distribution in Hawaii in non-prescription sunscreens. The 6 Department has the following comments. 7 The Department recognizes the benefits of the 2018 Act 104 prohibiting the sale of 8 oxybenzone and octinoxate containing sunscreen products in Hawaii. It is heartening to see the 9 dramatic increase in availability, variety and consumer acceptance of oxybenzone and 10 octinoxate-free options and mineral sunscreen products that have entered the consumer market in 11 the past few years. Use of these products meets standards for public health protection and offers 12 the public a concrete choice to help protect Hawaii’s coral reefs and marine environment when 13 enjoying our beaches. However, the risk of skin cancer from sun exposure remains a hazard for 14 the people of Hawaii and visitors and it is imperative to consider the potential public health 15 consequences of additional prohibition on sunscreen ingredients.
    [Show full text]